Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials AdvanceDefense World · Sep 28, 2026
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials AdvanceMarketBeat · Sep 27, 2026
Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s WhyDefense World · Sep 27, 2026
Nkarta to Participate in September Investor ConferencesGlobeNewsWire · Sep 10, 2026
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026GlobeNewsWire · Sep 8, 2026
6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.Defense World · Sep 4, 2026Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.36 | -$0.54 | Miss |
| May 12, 2026 | -$0.39 | -$0.37 | Beat |
| Mar 25, 2026 | -$0.32 | -$0.37 | Miss |
| Nov 10, 2025 | -$0.32 | -$0.29 | Beat |
| Aug 12, 2025 | -$0.37 | -$0.31 | Beat |
| May 14, 2025 | -$0.44 | -$0.43 | Beat |